

December, 10-12 | Boston, MA
www.complement-therapeutics.com

REGISTER BY
DECEMBER 9 &
SAVE UP TO \$100!



8th Annual

Complement-Based Drug Development Summit

Achieving Efficacy & Exploring Indication Expansion for Complement Inhibitors

Evaluating Intervention Points in the Complement Cascade to Achieve & Improve Efficacy & Advance the Next Generation of Inhibitors for Inflammatory Diseases

Expert Speakers Include:



Michael Holers
Professor of Medicine
University of Colorado



Michael Storek
Head of Complement Cluster
Sanofi



James Hamilton
Chief of Discovery & Translational Medicine
Arrowhead Pharmaceuticals



Lori Taylor
Senior Vice President – Portfolio Strategy & Operations
Annexon Biosciences



Shiyu Wang
Co-Founder & Chief Scientific Officer
Sanogene Bio



Jeffrey Stavenhagen
Chief Scientific Officer
Dianthus Therapeutics

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.complement-therapeutics.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 8th Complement-Based Drug Development Summit

8th Annual
Complement-Based Drug Development Summit
December, 10-12, 2024 | Boston, MA

With the community hailing the latest FDA-approved therapeutic with Novartis' inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?

With assets in nephrology, ophthalmology, neurodegeneration, and inflammation all progressing through to the clinic, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies.

Join 100+ industry leaders, scientists, and clinicians at the premier, end-to-end, 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies. Across 3 days of content, you can expect discussions spanning:

- Strategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets
- Navigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication
- Exploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort
- Moving from targeting rare disease with complement inhibitors to larger patient populations
- Navigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster

KEY BENEFITS OF ATTENDING



Delve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with **Apteron Therapeutics**, **Annexon Bio**, and **Sanofi** to determine the most effective pathway when developing complement inhibitors



Explore the potential for combination therapies with existing complement therapies and other modalities with **CSL Behring** for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.



Discuss the move from targeting rare diseases with complement inhibitors to more common diseases with **IgM Biosciences**, **Grid Therapeutics**, and **Astellas**, to target larger patient populations



Evaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with **Beacon Therapeutics** and **Arrowhead Pharmaceuticals**



8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval

What our speakers have to say:

Great speakers and well organized networking opportunities

CEO, Cascade Biotechnologies

Intimate setting with lots of pharma to network with and pitch ideas to, along with clinically relevant presentations

Taxiarchis Kourelis, Associate Professor of Medicine – Hematology, Mayo Clinic

I liked the focused nature of the conference, that is focusing on one key system of pathology, and all therapeutic development in this area

Vertex Pharmaceuticals

Your 22 Expert Speakers

8th Annual
Complement-Based Drug
Development Summit
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Nirmal Banda
Professor
University of Colorado



Andrew Cook
Senior Director –
Discovery Chemistry
Apellis Pharmaceuticals



James Hamilton
Chief of Discovery &
Translational Medicine
**Arrowhead
Pharmaceuticals**



Michael Holers
Professor of Medicine
University of Colorado



Martin Kolev
Associate Director –
Complement Science
Apellis Pharmaceuticals



Alexandra Lucas
Founding Scientist
Serpas Biologics



Maciej Markiewski
Professor
Texas Tech University



Edward Patz
CEO
Grid Therapeutics



Alex Pellerin
Director of Preclinical
Translation
Seismic Therapeutics



Emma Persson
Clinical Scientist
Argenx



Horia Pribiag
Research Scientist
The Broad Institute



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics



Jeffrey Stavenhagen
Chief Scientific Officer
Dianthus Therapeutics



Michael Storek
Head of Complement
Therapeutics
Sanofi



Lori Taylor
Senior Vice President
- Portfolio Strategy &
Operations
Annexon Biosciences



Axel Vater
Founder & Chief Scientific
Officer
Aptarion Biotech



Karthik Viswanathan
Vice President -
Research
Visterra



Shiyu Wang
Co-Founder & Chief
Scientific Officer
Sanegene Bio



Karina Yazdanbakhsh
Vice President & Head
of Complement Bio
Laboratory
New York Blood Centre



Deepak Jain MD, MBA
Vice President - Global
Program Team Leader
**Alexion, AstraZeneca
Rare Disease**



Kevin Hunt
Chief Scientific Officer
Vanqua Bio



Tim Scott
Clinical Research Scientist
Machaon Diagnostics



Manuel Galvan
Director - Complement
Laboratory and Advanced
Diagnostic Laboratories
National Jewish Health

Pre-Conference Workshop Day

Tuesday, December 10

8th Annual
Complement-Based Drug
Development Summit
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Registration & Morning Coffee

8.30

Workshop A

9.00 - 11:30

Mastering the Complement System: Strategic Targeting & Preclinical Breakthroughs for Next-Generation Complement Inhibitors

Provides an in-depth exploration of the complement system and its therapeutic targeting for diseases. Gain comprehensive insights into the complexities of complement pathways, the strategic selection of inhibition targets, and the essential steps in preclinical development to:

- Delve into the intricacies of the complement system, with a focus on identifying critical nodes and pathways (classical, lectin, and alternative) for potential therapeutic intervention
- Understand the underlying mechanisms driving complement activation and regulation, and learn to pinpoint specific proteins or pathways that are most promising for therapeutic targeting

Workshop Leaders



Martin Kolev
Associate Director
of Complement
Apellis



Andrew Cook
Senior Director
– Discovery
Chemistry
Apellis

Lunch Break & Networking

11.30

Workshop B

12.30 - 3.00

From Bench to Bedside: Streamlining Preclinical Strategies for Effective Complement Drug Development Across Disease Indications

A comprehensive guide to improving the efficacy measurement and translational success of complement inhibitors. Explore cutting-edge methodologies and best practices in preclinical research to bridge the gap between laboratory findings and clinical application.

- Conduct detailed dose-response studies to determine the optimal dosing regimen that maximizes efficacy while minimizing toxicity
- Perform extensive safety and toxicology studies in multiple animal species to identify potential side effects and establish a safety profile
- Examine the latest animal models to better mimic human responses

Workshop Leader



Jeffrey Stavenhagen
Chief Scientific
Officer
**Dianthus
Therapeutics**



Axel Vater
Founder & Chief
Scientific Officer
Aptarion Biotech

End of Pre-Conference Workshop Day

3.00

Conference Day One

Wednesday, December 11

8th Annual
**Complement-Based Drug
Development Summit**
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



7.20 Morning Registration & Coffee



Michael Holers
Professor of Medicine
**University of
Colorado**

8.20 Chair's Opening Remarks

Advancing Complement Therapies: Pathways, Clinical Insights & Future Directions

8.30 Panel Discussion: Dysregulation Insights: An Overview of the Complement System in Health & Human Disease



- Unravelling the 3 complement pathways and potential intervention points
- Understanding core processes in healthy inflammatory response in comparison to pathophysiology of autoimmune conditions
- Discussing the optimal modalities for delivering complement mediated drugs: small molecules, antibodies, and gene therapies



Michael Holers
Professor of
Medicine
**University of
Colorado**



Michael Storek
Head of Complement
Therapeutics
Sanofi



Maciej Markiewski
Professor
**Texas Tech
University**



Karina Yazdanbakhsh
Vice President & Head
of Complement Bio
Laboratory
**New York Blood
Centre**

9.00

The Role of Haem in the Complement System

- Haem-binding proteins in regulating complement activation
- Pathophysiological mechanisms underlying haem-induced tissue damage
- Development of haem-binding proteins or complement inhibitors to prevent haem-mediated complement activation



Tim Scott
Clinical Research
Scientist
Machaon Diagnostics

9.30

Clinical Validation of the Modified Ham 2.0 Test to Aid the Diagnosis & Treatment of Complement-Mediated Diseases

- Introducing mHam 2.0, a novel cell-based clinical assay for diagnosing and treating complement-mediated diseases
- How using the mHam 2.0 can help develop and evaluate new complement drug candidates or optimize clinical trial subject recruitment



Deepak Jain MD, MBA
Vice President - Global
Program Team Leader
**Alexion, AstraZeneca
Rare Disease**

9.45

Complement Combinations: Exploring Potential of Complement Inhibitor Combinations in Patients with PNH



- Importance of sustained control of terminal complement activity to prevent the most severe consequences of PNH
- Role of proximal complement inhibition without compromising terminal complement inhibition in patients with PNH



10.15 Speed Networking

This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders in the complement targeting field. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progress in modulating, inhibiting and activating the complement system.



10.45 Morning Break

Conference Day One

Wednesday, December 11

8th Annual
Complement-Based Drug Development Summit
December, 10-12, 2024 | Boston, MA



James Hamilton
Chief of Discovery &
Translational Medicine
**Arrowhead
Pharmaceuticals**



Targeting Complement Factor B with siRNA: Concept to Clinic

- Lessons learned from discovery and early preclinical complement inhibitor studies
- Using Complement Factor B inhibitors to target the alternative pathway
- Evaluating safety, tolerability, PK/PD in C3 and Factor B inhibitors to treat renal disease

Optimizing Complement Targeting Strategies: Acute vs. Chronic Inflammation & Homeostasis

11.45 Panel Discussion: Upstream, Downstream or Proximal – Where, When, & How to Target?



- Discussing acute versus chronic inflammatory disorders and which proteins within the cascade we can target
- Understanding disease progression and debating systemic or tissue specific targeting
- Can combination therapies bridge the gaps and ensure efficacy for treatment?



Axel Vater
Founder & Chief
Scientific Officer
Aptarion Biotech



Lori Taylor
Senior Vice President
- Portfolio Strategy &
Operations
Annexon Biosciences



Karthik Viswanathan
Vice President -
Research
Visterra



Alex Pellerin
Director of Preclinical
Translation
Seismic Therapeutics



Manuel Galvan
Director - Complement
Laboratory and
Advanced Diagnostic
Laboratories
**National Jewish
Health**

12.15 National Jewish Health; Balancing Diagnostic Testing, Clinical Trial Support & Assay Innovation in the Complement Space



12.30 Lunch



Lori Taylor
Senior Vice President
- Portfolio Strategy &
Operations
Annexon Biosciences



1.30 GBS vs. GA: Treating Both Acute & Chronic Diseases with C1q Inhibition

- Discussing the efficacy of ANX005 in treating Guillain-Barre Syndrome
- Optimizing dosage for acute and chronic indications
- Summarizing the differences in the challenges of complement inhibition in acute and chronic indications

Recent Advancements & Exploring When to Pursue RNAi & Gene Therapies



Shiyu Wang
Co-Founder & Chief
Scientific Officer
Sanegene Bio



2.00 Ligand & Enhancer Assisted Delivery for RNAi Complement Inhibitors

- Targeting C3 with siRNA
- Delivering a GalNAc conjugate to the liver using the LEAD GalNAc platform
- Discussing optimal dosage for long-term efficacy



2.30 Afternoon Break & Poster Session

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the Complement-Based Drug Development world. Don't miss out on the chance to submit your own posters and get ready to connect, learn, and present.
To submit your poster for the session, please contact info@hansonwade.com

Conference Day One

Wednesday, December 11

8th Annual
Complement-Based Drug
Development Summit
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Nirmal Banda
Professor
University of
Colorado

3.00 RNAi Therapeutics Coming of Age: Targeting Complement Genes to Treat Rheumatoid Arthritis

- siRNAs to target the “undruggable” candidates and how these fit within the complement cascade
- Considering tissue specific targeting to ensure healthy complement activity remains
- Clinical data updated for the use of siRNA-based complement inhibitors in Rheumatoid Arthritis

3.30 Roundtable Discussion: Assays, Biomarkers & Computational Modelling in Complement Inhibitor Development



This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation. Topics to consider:

Improving Reliability &
Making Informed Assay
Choices for Complement
Based Drugs

Validating Qualitative &
Developing Quantitative
Biomarkers for
Complement

Mimicking Mechanistic
Understanding
through Computational
Modelling



Closing this session with an audience wide discussion on enhancing assay reliability, biomarker validation, and computational modelling in complement-based drug development to better standardize comparison of results across the field.



Michael Holers
Professor of Medicine
University of
Colorado

4.00 Chair's Closing Remarks

4.10 End of Conference Day 1

“ It was great to hear about the current status of clinical-stage programs in the field, new and exciting preclinical research, and thought-provoking discussion from the audience! ”

Sanofi

Conference Day Two

Thursday, December 12

8th Annual
Complement-Based Drug Development Summit
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



7.45 Morning Registration & Coffee

8.20 Chair's Opening Remarks

Targeting the Complement System for Breakthroughs in Oncology



Edward Patz
Chief Executive Officer
Grid Therapeutics



8.30 **Antibodies, Complement, and Anti-Tumour Immunity**

- Increasing evidence implicates complement activities in oncology
- Targeting complement factor H
- Conceptualizing drug development targeting angiogenesis in oncology



Maciej Markiewski
Professor
Texas Tech University

9.00 **Complement in Oncology**

- Rationale for targeting complement in cancer therapy
- Preclinical and clinical data supporting complement inhibition in oncology
- Challenges and opportunities in developing complement-targeted therapies
- Combination therapies with other cancer treatments

9.30 **Panel: The Past, Present & Future of Complement in Oncology**

- Where to target for oncology indications?
- Discussing complement dependent mechanisms in angiogenesis
- How can newly discovered complement functions be targeted for therapy?



Edward Patz
Chief Executive Officer
Grid Therapeutics



Maciej Markiewski
Professor
Texas Tech University



Bruce Keyt
Chief Scientific Officer
IgM Biosciences



10.00 Morning Break

Precision Medicine in CNS Diseases: The Role of Complement Inhibition



Horia Pribiag
Research Scientist
The Broad Institute

10.30 **Targeting complement receptor C3aR in neuroinflammatory CNS disorders**

- Unravelling the role of complement in neurodegenerative and psychiatric conditions
- Development of brain-penetrant small molecule inhibitors of C3aR
- Evaluating pharmacodynamic biomarkers of complement inhibition in preclinical models of neurodegeneration



Emma Persson
Clinical Scientist
Argenx



11.00 **Phase 2 Clinical Study into Empasiprubart for Multifocal Motor Neuropathy**

- Targeting C2 to inhibit function and downstream complement activation
- Reducing tissue inflammation and adaptive immune responses in autoimmune indications
- Clinical update on Empasiprubart for MMN



Kevin Hunt
Chief Scientific Officer
Vanqua Bio

11.30 **Discovery of Next Generation C5aR1 Antagonists for Peripheral and CNS Indications: Enhancing Target Coverage While Reducing Safety Liabilities**



12.00 Lunch



8

+1 617 455 4188 @ info@hansonwade.com

www.complement-therapeutics.com



Conference Day Two

Thursday, December 12

8th Annual
Complement-Based Drug
Development Summit
December, 10-12, 2024 | Boston, MA

Complement in Ophthalmology

1.00 Upstream vs. Downstream Targeting in GA & AMD

- Discussing the advantages and disadvantages of different complement targets through an ophthalmology lens
- Delivering complement inhibitors to the eye: topical, intravitreal, or systemic?
- Future considerations for combination therapies to target multiple complement components in the eye



Shiyu Wang
Co-Founder & Chief Scientific Officer
Sanegene Bio



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics

1.30 Roundtable: Optimizing Dosage and Managing Off-Target Effects to Improve Patient Outcomes

This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation. Topics to consider:



Optimizing Dosage Studies to Bring Safe Complement-Targeting Drugs to Patients

Examining Off Target Effects of Complement Drugs & Potential Combinations

Delving Into Personalized Medicine Approaches for Optimizing Complement Inhibitor Therapy



Closing this session with an audience wide discussion on improving the clinical development of complement-based drugs to reduce bottlenecks from bench to bedside.



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics



2.00 Preclinical Updates for Complement Regulators Using Gene Therapies

- The benefits of using gene therapies to target complement mediated diseases
- Using a localised approach to target the eye and mitigate toxicity
- Updates in targeting Geographic Atrophy/Dry AMD



2.30 Afternoon Break

Innovative Horizons in Complement Drug Discovery: Future Opportunities & Next-Generation Therapies



Alexandra Lucas
Founding Scientist
Serpass Biologics

3.00

Virus-derived Serpins as a Novel Modality for Specific Targeting & Competitive Inhibition

- Virus derived SERPINS as a potential therapeutic for complement inhibition
- Improving selectivity of targets in the complement cascades using virus like therapeutics

3.30 Panel Discussion: Novel Modalities & Next Generation of Complement Inhibitors



- Where is the next step for complement inhibitors?
- Examine the past, present, and future, of complement inhibitors for autoimmune conditions and they may fit alongside existing therapies



Michael Storek
Head of Complement Therapeutics
Sanofi



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics



Maciej Markiewski
Professor
Texas Tech University

4.00 Chair's Closing Remarks

4.10 End of Conference Day 2



+1 617 455 4188 @ info@hansonwade.com
www.complement-therapeutics.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Partner With Us

8th Annual
Complement-Based Drug
Development Summit
December, 10-12, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Exclusive Opportunity to Position Yourself as the Go-To Company for the Complement-Based Therapeutics Field

This expanding community of drug developers are constantly looking out for new partners to help them overcome their drug development bottlenecks such as:



Sourcing patient samples for therapeutic monitoring of complement targeting



Immunoassays for diagnosis, monitoring complement levels and toxicology studies



Reagent providers for discovery and preclinical studies



Selective and specific antibody providers for complement biology




Relevant disease models that accurately reflect *in vivo* biology

As one of our select event partners, you'll gain the exclusive opportunity to showcase your brand and connect with key stakeholders to contribute to the advancement of the rapidly evolving complement field.

Put your services and your brand in front of end-to-end experts in immunology and ensure your services are central to their processes. From immunoassays to activation diagnostics, functional testing, antibody and reagent providers, no matter what your offering, we will work with you to ensure you capitalize on this opportunity.

SENIORITY OF ATTENDEES*



C-Level: 18%

President/VP: 15%

Director: 29%


Manager: 5%

Scientist: 13%

Professor: 5%

Other: 15%

TYPES OF COMPANIES ATTENDING*



Drug Developer
Healthcare Providers
Equipment & Service Providers
Research Institute
Other

*Based on the 7th Complement-Based Drug Development Summit 2023

GET INVOLVED



Ezgi Vedat-Irikzade
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Innovation Partner

National Jewish Health Advanced Diagnostic Laboratories offer preclinical, clinical safety/tox and biomarker efficacy testing services under CAP/CLIA/ISO15189 guidelines. Our Complement Laboratory offers the most comprehensive test menu in the industry. Customized study design and data analysis based on the experience from 100+ studies filed with regulatory agencies, assessing patient status, target engagement, complement activation and immune complex formation for small molecule, biologics, vaccines and oligonucleotide-based therapeutics.

www.nationaljewish.org



Innovation Partner

Machaon Diagnostics provides industry-leading rapid turnaround times* and expedited trial services. Our scientific expertise is coagulation, platelet, complement, genetic and rare disease. Hospitals, pharma, and CROs trust our specialized laboratory. We also offer Rare Disease Subject, Sample and Site Finder. Machaon Diagnostics comprises two CAP/CLIA accredited reference laboratories, a central laboratory, and a Rare Disease CRO.

*e.g., clinical NGS gene sequencing in 48 hours; sC5b-9 levels in <24 hours (7 days/week)

www.nationaljewish.org



Exhibition Partner

Exsera BioLabs is a specialty complement laboratory that maintains CAP/CLIA certification and compliance with the FDA GLPs and GCPs. Our mission is to serve as an integrated network of niche laboratories, providing esoteric testing to support patient diagnostics and biomarker translation. We collaborate with researchers, biotech firms, and pharmaceutical companies to advance scientific discoveries and support drug development goals.

Our leadership, Director, Dr. Frazer-Abel, and our Associate Director, Dr. Nandakumar, have a combined over three decades of experience in complement, autoimmune and immunoinflammatory testing; even our laboratory team brings an average of over 10 years of expertise to every project. We pride ourselves on delivering quality and timely results, offering insights that truly make a difference in your work.

Situated at the University of Colorado's Anschutz Medical Campus, Exsera BioLabs is at the forefront of complement immunobiology. This prime location enables us to leverage a vibrant scientific community dedicated to advancing patient care and health outcomes.

As a recognized leader in our field, we are excited to have built this enterprise from the ground up, to enable us to offer specialized services that benefit our clients and their endeavors. By providing tailored services that address unique challenges and opportunities, we look forward to contributing to the success of our clients and their projects.

www.exserabiolabs.org



Exhibition Partner

Our belief is that together we can improve health! By being a reliable (service) partner with almost 30 years of knowledge in the complement field, we know that quality and trust in your development is key. Our standard assay and antibodies as well as any customization or service are performed with this in mind and together, we can improve health. Currently we are working for multiple pharma companies to improve health, speed up drug development and monitoring. We look forward to also working with you.

www.hycultbiotech.com

GET INVOLVED



Ezgi Vedat-Irikzade

Partnerships Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com



Exhibition Partner

QuidelOrtho Specialty Products Group (SPG) Complement System products are a well established name in immune system monitoring, providing a variety of first-in-class diagnostic and research solutions. The SPG product portfolio includes ELISA assays, multiplex, antibodies, proteins, and sera based products such as depleted sera, normal human serum, and cobra venom factor. Our products cover many of the intact and activation proteins of the complement system for a comprehensive product portfolio.

www.quidel.com/spg



Exhibition Partner

Svar Life Science is a Swedish life science company dedicated to providing our partners with advanced technology platform, such as Functional Complement biomarker and screening assays and Cell-based Reporter Gene assays, as well as unique service models for Bioassays customization, Custom cell line development in combination with GxP Laboratory Services – all designed to meet our customers specific project needs.

www.svarlifescience.com



Event Partner

The Centre for Human Drug Research (CHDR) is an independent institute that specialises in cutting-edge early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximise their clients' success. In addition, CHDR places the highest priority on their subjects' comfort and safety, and they play an active role in helping educate the medical and clinical research communities.

www.chdr.nl

“This event is a great opportunity to learn other exciting clinical and pre-clinical programs in the complement space.”

Inflarx

GET INVOLVED



Ezgi Vedat-Irikzade
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.complement-therapeutics.com



Tel: +1 617 455 4188



Email: info@hansonwade.com

SAVE \$100!

Showcase your brand to distinguish yourself from your complement-based competitors

Connect with the key decision-makers at the for front of the complement-based field to foster new and existing relationships

Gain visibility and recognition as an inflammation industry leader to set yourself up for commercial success

Understand current targeting, toxicology, and efficacy challenges, shortfalls, and opportunities for improvement in complement drug development

Contribute to the rapidly evolving field to bring better complement inhibitors to patients faster

Drug Developers**	Register & Pay By December 9	On the Door
Conference + 3 Workshops	\$4,097 (Save \$100)	\$4,197
Conference + 2 Workshops	\$3,697 (Save \$100)	\$3,797
Conference + 1 Workshop	\$3,298 (Save \$100)	\$3,398
Conference Only	\$2,899 (Save \$100)	\$2,999
Academic & Researchers***	Register & Pay By December 9	On the Door
Conference + 3 Workshops	\$3,497 (Save \$100)	\$3,597
Conference + 2 Workshops	\$3,164 (Save \$100)	\$3,264
Conference + 1 Workshop	\$2,831 (Save \$100)	\$2,931
Conference Only	\$2,499 (Save \$100)	\$2,599
Service Provider Pricing	Register & Pay By December 9	On the Door
Conference + 3 Workshops	\$4,997 (Save \$100)	\$5,097
Conference + 2 Workshops	\$4,530 (Save \$100)	\$4,630
Conference + 1 Workshop	\$4,065 (Save \$100)	\$4,165
Conference Only	\$3,599 (Save \$100)	\$3,699

Team Discounts

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

* To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

***To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Venue

Hilton Boston Logan Airport, One Hotel Dr, Boston, MA 02128, United States

For further information or assistance, please visit:

<https://www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

